¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"specific substrate concentration"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • stress concentration
    ÀÀ·ÂÁýÁß
  • subanesthetic concentration
    ¸¶Ãë´úµÈ³óµµ, ¸¶Ãë¹Ø³óµµ, Áظ¶Ãë³óµµ
  • smoke concentration
    ¸Å¿¬³óµµ
  • urinary solute concentration
    ¿ä¿ëÁú³óµµ
  • age-specific death rate
    ¿¬·Éº°»ç¸Á·ü
  • age-specific fertility rate
    ¿¬·Éº°»ý½Ä·ü
  • age-specific rate
    ¿¬·Éº°ºñÀ²
  • cause-specific rate
    ¿øÀκ°ºñÀ²
  • donor-specific phage
    Á¦°øÀÚÆ¯ÀÌÆÄÁö, °ø¿©ÀÚÆ¯ÀÌÆÄÁö
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group-specific
    ±ºÆ¯ÀÌ-
  • group-specific antigen
    ¹«¸®Æ¯ÀÌÇ׿ø, ±ºÆ¯ÀÌÇ׿ø
  • neuron-specific enolase
    ´º·±Æ¯ÀÌ¿¡³î¶ó¾ÆÁ¦
  • organ specific antigen
    Àå±âƯÀÌÇ׿ø
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • subanesthetic concentration
    ¸¶Ãë´úµÈ³óµµ, ¸¶Ãë¹Ø³óµµ
  • urinary solute concentration
    ¿ä¿ëÁú³óµµ
  • egg concentration technique
    Áý¶õ¹ý
  • particle concentration fluorescence
    ÀÔÀÚ³óÃàÇü±¤
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£
  • age-specific rate
    ¿¬·Éº°Æ¯¼öÀ²
  • age-specific death rate
    ¿¬·Éº°Æ¯¼ö»ç¸Á·ü
  • age-specific fertility rate
    ¿¬·Éº°Ãâ»êÀ²
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • organ specific antigen
    Àå±âƯÀÌÇ׿ø
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • specific action
    ƯÀÌÀÛ¿ë
  • specific activity
    ºñ¹æ»ç´É, ƯÀÌȰ¼ºµµ
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • group-specific antigen
    ±º-ƯÀÌÇ׿ø
  • idiotype specific regulatory cell
    °³º°Æ¯ÀÌÇü Á¶Àý¼¼Æ÷
  • immunity, specific
    ƯÀ̸鿪
  • platelet-specific antigens
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • pneumococcal [specific] polysaccharide
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • polysaccharide, pneumococcal [specific]
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • prostate specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø
  • prostate-specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø(îñí¡àÍ÷åì¶ù÷ê«)
  • prostatic specific antigen
    Àü¸³¼± ƯÀÌÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hemoglobin content/concentration
    Ç÷»ö¼ÒÇÔ·®/³óµµ
  • hydrogen ion concentration
    ¼ö¼ÒÀ̿³óµµ.
  • inhibitory concentration, minimum (MIC)
    ¾ïÁ¦ÃÖ¼Ò³óµµ
  • least concentration =LC
    ÃÖÀú³óµµ(õÌî¸ÒØöô).
  • least concentration time =LCT
    ÃÖÀú³óµµ½Ã°£(¡­ãÁÊà).
  • lethal concentration
    Ä¡»ç³óµµ
  • limiting concentration
    ÇѰè³óµµ(¡­ÒØöô).
  • maximum allowable concentration =MAC
    ÃÖ´ëÇã¿ë³óµµ(õÌÓÞúÉé»ÒØöô).
  • maximum permissible concentration =MP
    ÃÖ´ëÇã¿ë³óµµ(¡­úÉé»ÒØöô).
  • maximum permissible concentration =MPC
    ÃÖ´ëÇã¿ë³óµµ(¡­úÉé»ÒØöô).
  • mchc=nmean corpuscular hemoglobin concentration
    Æò±ÕÀûÇ÷±¸Ç÷»ö¼Ò³óµµ(¡­ÒØÓø)
  • mean cell hemoglobin concentration
    Æò±ÕÀûÇ÷±¸Ç÷»ö¼Ò³óµµ
  • mean corpuscular hemoglobin concentration
    Æò±ÕÀûÇ÷±¸Ç÷»ö¼Ò³óµµ(øÁгîåúìϹúìßäáÈÒØÓø)
  • mean corpuscular hemoglobin concentration =MCHC
    Æò±ÕÀûÇ÷±¸Ç÷»ö¼Ò³óµµ(Ì°Ë»ËøÌ´Ë´Ì´Ë×ËÛËÀ̬).
  • mean corpuscular hemoglobin concentration =MCHC
    Æò±ÕÀûÇ÷±¸Ç÷»ö¼Ò³óµµ(øÁгîåúìϹúìßäáÈÒØöô).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • substrate
    ±âÁú(Ðñòõ)
  • substrate anchoring
    ±âÁú °íÁ¤(ÐñòõͳïÒ)
  • substrate-assisted catalysis
    ±âÁúº¸Á¶ Ã˸Å(ÐñòõÜÍð¾õºØÚ)
  • substrate-binding site
    ±âÁú°áÇÕ (ÐñòõÌ¿ùê) ÀÚ¸®
  • substrate-bridge complex
    ±âÁú°¡±³ º¹ÇÕü(ÐñòõÊ­ÎéÜÜùêô÷)
  • substrate constant
    ±âÁú»ó¼ö (ÐñòõßÈâ¦)
  • substrate cycle
    ±âÁúȸ·Î (ÐñòõüÞÖØ)
  • substrate elution chromatography
    ±âÁú¿ëÃâ (ÐñòõéÁõó) Å©·Î¸¶Åä±×·¡ÇÇ
  • substrate inhibition
    ±âÁúÀúÇØ (ÐñòõîÁúª)
  • substrate phosphorylation
    ±âÁú ÀλêÈ­ (Ðñòõ×òß«ûù)
  • substrate synergism
    ±âÁú »ó½ÂÀÛ¿ë(Ðñòõß¾ã°íÂéÄ)
  • suicide substrate
    ÀÚ¸ê ±âÁú(í»ØþÐñòõ)
  • variable substrate
    °¡º¯±âÁú(ʦܨÐñòõ)
  • venom substrate
    »çµ¶(ÞïÔ¸) ±âÁú(Ðñòõ)
  • apparent specific volume
    ¿Ü°ß(èâ̸) ºñ(Ýï)¿ëÀû(é»îÝ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CCS Canadian Cardiovascular Society; casualty clearing station; cell cycle specific; cholecystosonograph...
ASP abnormal spinal posture; acute symmetric polyarthritis; African swine pox; aged substrate plasma; al...
BSS Bachelor of Sanitary Science; balanced salt solution; Bernard-Soulier syndrome; black silk suture; b...
DS dead air space; dead space; deep sedative; deep sleep; defined substrate; dehydroepiandrosterone sul...
ES ejection sound; elastic stocking; electrical stimulus, electrical stimulation; electroshock; emergen...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SRS substrate recognition site
( ATP ATP concentration
ATP]i ATP concentration
AUC Area under concentration-time curve
AUC Area under the concentration curve
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • specific criteria
    ƯÀÌÇÑ ±âÁØ
  • specific dentist-patient relationship
    µ¶Æ¯ÇÑ Ä¡°ú ÀÇ»ç-ȯÀÚ °ü°è
  • specific energy of sense
    Ư¼ö °¨°¢ ¿¡³ÊÁö
  • specific gamma emission
    Ư¼ö °¨¸¶ ¹æÃâ
  • specific gravity test
    ºñÁß ½ÃÇè
  • specific humoral immunity
    ƯÀ̼º ü¾× ¸é¿ª
  • specific inflammation
    ƯÀ̼º ¿°Áõ
  • specific membrane receptor
    ƯÁ¤ ¸· ¼ö¿ë±â
  • specific opiate receptor site
    Ưº°ÇÑ ¾ÆÆí ¼ö¿ëºÎ
  • specific receptor
    ƯÀÌ ¼ö¿ëü, ƯÀÌ ¼ö¿ë±â
  • specific region
    ƯÀÌ ºÎÀ§
  • specific tender point site
    ƯÁ¤ ¾ÐÅëÁ¡
  • specific weight
    ºñÁß
  • tumor specific transplantation
    Á¾¾ç ƯÀ̼º À̽Ä
  • virus-specific surface antigen
    ¹ÙÀÌ·¯½º ƯÀ̼º Ç¥¸é Ç׿ø ¹ÙÀÌ·¯½º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
age-specific rate A rate for a specified age group, in which the numerator and denominator refer to the same age group.
(05 Mar 2000)
Bensley's specific granules Granule's in the cells of the islands of Langerhans in the pancreas.
(05 Mar 2000)
brain-specific kinase <enzyme> Expressed specifically in brain; member of the eph/elk receptor-like kinase family; mw 105 kD; may represent murine homolog of chicken cek7 receptor-like kinase; amino acid sequence given in first source
Registry number: EC 2.7.1.-
Synonym: bsk tyrosine kinase
(26 Jun 1999)
galactosyl-1-3-N-acetylgalactosaminyl-specific 2,6-sialyltransferase <enzyme> Genbank x77775
Registry number: EC 2.4.99.-
Synonym: galbeta1,3galnac 2,6-sialyltransferase, st6galnac II
(26 Jun 1999)
glycoprotein hormone-specific N-acetylgalactosamine transferase <enzyme> Transfers galnac to the terminal glcnac moieties of glcnac2man3glcnac2asn
Registry number: EC 2.4.1.-
Synonym: ghs-acgalnh2 transferase, glycoprotein hormone galnac transferase, glycoprotein hormone - n-acetylgalactosaminyltransferase
(26 Jun 1999)
retina-specific amine oxidase <enzyme> Genbank d88213
Registry number: EC 1.4.-
Synonym: rao enzyme, human
(26 Jun 1999)
Gomori's non-specific acid phosphatase stain <technique> A method in which formalin-fixed frozen sections are incubated in a substrate containing sodium beta-glycerophosphate and lead nitrate at pH 5.0; the insoluble lead phosphate produced is treated with ammonium sulfide to give a black lead sulfide.
(05 Mar 2000)
Gomori's non-specific alkaline phosphatase stain <technique> A calcium-cobalt sulfide method using frozen sections or cold acetone-or formalin-fixed paraffin sections, plus sodium beta-glycerophosphate as a substrate at pH 9.0 to 9.5 with Mg++ as activator; calcium ions precipitate the liberated phosphate, cobalt salt replaces the calcium phosphate, and ammonium sulfide converts the product to a black cobalt sulfide.
(05 Mar 2000)
group-specific protease <enzyme> A serine protease, obtained from rat small intestine, which preferentially inactivates the apo forms of certain pyridoxal phosphate requiring enzymes
Registry number: EC 3.4.21.-
(26 Jun 1999)
RNA, transfer, amino acid-specific A group of transfer rnas which are specific for carrying each one of the 20 amino acids to the ribosome in preparation for protein synthesis.
(12 Dec 1998)
poly A specific exoribonuclease <enzyme> Acts on 2' or 3'-linked oligoriboadenylates to liberate 5'-AMP
Registry number: EC 3.1.13.-
Synonym: 2',3'-exoribonuclease, 3'-exoribonuclease
(26 Jun 1999)
poly(A)-specific ribonuclease <enzyme> From vigna unguiculata seedlings; bifunctional enzyme responsible for both poly(a)-polymerizing and poly(a)-hydrolyzing activities; removes the poly(a) tail as the first step in degrading mRNA
Registry number: EC 3.1.13.4
Synonym: poly(a) nuclease, mRNA poly(a) nuclease, poly(a) ribonuclease (pan), pan2 protein
(26 Jun 1999)
myelencephalon-specific serine protease <enzyme> Specifically expressed in the nervous system; plays a role in normal homeostasis and response of spinal cord to injury.
Registry number: EC 3.4.21.-
Synonym: myelencephalon-specific protease, msp enzyme
(26 Jun 1999)
pregnancy-specific beta 1-glycoprotein A glycoprotein with the electrophoretic mobility of a beta-1 globulin. It is produced by the placental trophoblast and secreted into the maternal bloodstream during pregnancy. It can be detected 18 days after ovulation and its concentration in plasma rises steadily until, at the end of gestation, it reaches 200 mg/ml. It has been proposed as a measure of placental function for fertility control and is a candidate for an early pregnancy test.
(12 Dec 1998)
prenylated peptide-specific endoprotease <enzyme> Cleaves c-terminal tripeptide from prenylated protein having c-terminal sequence caax; race is rac and a-factor converting enzyme with same activity
Registry number: EC 3.4.14.-
Synonym: prenylated protein endoprotease, race enzyme, isoprenylated protein endopeptidase, isoprenylated protein endoprotease
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á